Has Mounika Mandadi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $127,846 in general payments to Mounika Mandadi, MD across 263 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mounika Mandadi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mounika Mandadi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mounika Mandadi, MD

Hematology & Oncology · Louisville, KYNPI 1164654307

Payments from drug & device makers

$127,846in general payments, 2019–2025

Across 263 payments — averaging $486.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$68K
Genentech, Inc.$43K
Pfizer$11K
Puma Biotechnology, Inc.$1K
Daiichi Sankyo Inc.$869
Athenex Pharmaceutical Division, LLC$522
plus $4K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	40	$67,631
Genentech, Inc.	4	$42,684
Pfizer	18	$11,269
Puma Biotechnology, Inc.	6	$1,198
Daiichi Sankyo Inc.	18	$869
Athenex Pharmaceutical Division, LLC	2	$522
Johnson & Johnson	15	$289
Merck	17	$284
Amgen	17	$238
AstraZeneca(2 entities)	10	$209
Sanofi	6	$167
E.r. Squibb & Sons, L.L.C.	3	$156
Gen-probe, Inc.	1	$150
Astellas Pharma US Inc	6	$146
Eisai Inc.	7	$132
Gilead	6	$119
Beigene USA, Inc.	2	$105
Foundation Medicine, Inc.	5	$100
Bristol Myers Squibb	5	$99
Incyte Corporation	5	$90
AbbVie	4	$85
ADC Therapeutics America, Inc.	4	$76
Tersera Therapeutics LLC	3	$70
Boehringer Ingelheim	3	$69
Pharmaessentia USA Corporation	3	$67
Geron Corporation	2	$62
Genmab U.S., Inc.	3	$60
Lilly USA, LLC	3	$58
Genentech USA, Inc.	3	$58
GSK	3	$55
Stemline Therapeutics Inc.	3	$55
Seagen Inc.	3	$51
Sun Pharmaceutical Industries Inc.	2	$45
Regeneron Healthcare Solutions, Inc.	2	$45
Pharmacyclics LLC, An Abbvie Company	1	$44
Taiho Oncology, Inc.	3	$43
Servier Pharmaceuticals LLC	2	$39
Sumitomo Pharma America, Inc.	2	$34
Deciphera Pharmaceuticals Inc.	1	$32
Blueprint Medicines Corporation	1	$30
Bayer	2	$27
Mirati Therapeutics, Inc.	1	$25
Iovance Biotherapeutics, Inc.	1	$23
Takeda Pharmaceuticals U.S.A., Inc.	1	$20
Azurity Pharmaceuticals, Inc.	1	$20
Apellis Pharmaceuticals, Inc.	1	$19
Legend Biotech USA Inc.	1	$18
Rigel Pharmaceuticals, Inc.	1	$17
Springworks Therapeutics, Inc.	1	$16
G1 Therapeutics, Inc.	1	$16
Caris MPI, Inc.	1	$15
Secura Bio, Inc.	1	$14
Alnylam Pharmaceuticals Inc.	1	$14
Shield Therapeutics Inc	1	$14
Morphosys, US Inc.	1	$13
Ipsen Biopharmaceuticals, Inc	1	$13
Adaptive Biotechnologies Corporation	1	$13
Sobi, Inc	1	$12

How this compares

$127,846 in reported general payments places this provider in the 75th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$139,678

Medicare patients

441

Services billed

1,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Louisville

Joseph MalyLouisville$7M
Laila AgrawalLouisville$6.3M
Jaspreet GrewalLouisville$4.2M
Rebecca RedmanLouisville$2.1M
Vivek SharmaLouisville$1.9M
Rohit KumarLouisville$1.6M
Jeffrey HargisLouisville$1.3M
Goetz KloeckerLouisville$1.2M
Elizabeth RileyLouisville$746K
Adam LyeLouisville$706K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →